Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure;Efectos del carvedilol en la capacidad funcional, función ventricular izquierda, catecolaminas y estrés oxidativo en pacientes con insuficiencia cardíaca crónica

Revista Espanola de Cardiologia

Volumn 57, Issue 11, 2004, Pages 1053-1058

  Castro, Pablo ^a   Pérez, Osvaldo ^a   Greig, Douglas ^a   Díaz Araya, Guillermo ^a,b   Moraga, Francisco ^a   Chiong, Mario ^a   Troncoso, Rodrigo ^a   Padilla, Ivonne ^a   Vukasovic, Jose L ^b   Corbalán, Ramón ^a   Lavandero, Sergio ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Beta blockers; Catecholamines; Heart failure; Oxidative stress

Indexed keywords

ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CATALASE; CATECHOLAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; FUROSEMIDE; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NEUROHORMONE; NORADRENALIN; OXYGEN; SPIRONOLACTONE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; OXIDATIVE STRESS; OXYGEN CONSUMPTION; SCORING SYSTEM; WALKING;

EID: 19944408195     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13068166     Document Type: Article

References (36)

1. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
2. Dargie HJ, McMurray JV, McDonagh TA. Heart failure, implications of the true size of the problem. J Intern Med 1996;239:309-15.
3. Martínez-Sellés M, García JA, Prieto L, Frades E, Muñoz R, Díaz O, et al. Características de los pacientes ingresados por insuficiencia cardíaca según el estado de su función ventricular. Rev Esp Cardiol 2002;55:579-86.
4. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
5. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94: 2800-6.
6. Packer M, Bristow M, Cohn J, Colucci WS, Fowler MB, Gilbert EM, et al. For the U.S. Carvedilol Heart Failure Study Group: effect of carvedilol on morbity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
7. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13.
8. MERITH-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353: 2001-9.
9. Francis GS, Goldsmith SR, Levine TV, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370.
10. Francis GS, Benedict C, Jhonstone DE, Kirklin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular disfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
11. Givertz M, Colucci W. New targets for heart failure therapy: endothelin, inflamatory cytokines, and oxidative stress. Lancet 1998;352:S134-8.
12. Keith M, Geranmayegan A, Sole M, Kurian R, Robinson A, Omram AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
13. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2α in pericardial fluid of patients with heart failure: a potential rol for in vivo oxidant stress in ventricular dilation and progression to heart failure. Circulation 1998;97:1536-9.
14. Nakamura K, Kusano K, Nakamura Y, Nakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105:2867-71.
15. Kaye D, Johnston L, Vaddadi G, Brunner-LaRocca H, Jennings GL, Esler M. Mechanisms of carvedilol action in human congestive heart failure. Hypertension 2001;37:1216-21.
16. Mahler D, Weinberg D, Wells C, Feinstein A. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984;6:751-8.
17. Díaz-Araya G, Naranjo L, Godoy L, Squella J, Letelier M, Nuñez-Vergara L. Antioxidants effects of 1,4-dyhidropyridine and nitroso aril derivatives on brain cerebral slices. Gen Pharmacol 1998;31:385-91.
18. Misra H, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247:3170-5.
19. Beers R, Sizer I. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952;195:133-40.
20. Paglia D, Valentine W. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-69.
21. González-Juanatey J, Alegría E, García V, Pérez G, Ruiz J, Espinosa JS, et al. Empleo, de bisoprolol en la insuficiencia cardíaca. Resultados del estudio BISOCOR. Rev Esp Cardiol 2003;56:873-9.
22. Kukin M, Kalman J, Charney R, Levy D, Buchholz-Varley C, Ocampo ON, et al. Prospective randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51.
23. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
24. Gilbert EM, Shusterman N, Young S. For the Carvedilol Heart Failure Study Group: carvedilol reduces the risk of clinical deterioration in chronic heart failure. Circulation 1996;94:1-664.
25. Australia/New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995;92:212-8.
26. Australia/New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;346:375-80.
27. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999;83:1201-5.
28. Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, et al. Impaired chronotropic response to exercise in patients with congestive heart failure: Role of postsynaptic beta-adrenergic desensitization. Circulation 1989;80:314-23.
29. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heat failure. N Engl J Med 1984;311:819-23.
30. Khaper N, Rigatto C, Seneviratne C, Li T, Singal PK. Chronic treatment with propanolol induces antioxidant changes and protects against ischaemia-reperfusion injury. J Mol Cell Cardiol 1997;29:3335-44.
31. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kan D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999;85:357-63.
32. Josephson RA, Silverman HS, Lakatta EG, Stern MD, Zweier JL. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem 1991;266:2354-61.
33. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K, et al. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 1999;85:147-53.
34. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypettrophy induced by tumor necrosis factor and angiotensin II. Circulation 1998;98:794-9.
35. Kirshenbaum L, Singal P. A relative deficit in antioxidant reserve may contribute to cardiac failure. Am J Cardiol 1990;6:47-9.
36. Newton GE, Azevedo ER, Parker JD. Inotropic and sympathetic responses to the intracoronary infusion of a B2-receptor agonist: a human in vivo study. Circulation 1999;99:2402-7.